Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May:149:103843.
doi: 10.1016/j.dnarep.2025.103843. Epub 2025 May 2.

Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases

Affiliations
Review

Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases

Nicolas Call et al. DNA Repair (Amst). 2025 May.

Abstract

The joining of DNA single- and double-strand breaks (SSB and DSB) is essential for maintaining genome stability and integrity. While this is ultimately accomplished in human cells by the DNA ligases encoded by the LIG1, LIG3 and LIG4 genes, these enzymes are recruited to DNA breaks through specific interactions with proteins involved in break sensing and recognition and/or break processing. In this review, we focus on the interplay between the DNA break-activated poly (ADP-ribose) polymerases, PARP1 and PARP2, poly (ADP-ribose) (PAR) and the DNA ligases in DNA replication and repair. The most extensively studied example of this interplay is the recruitment of DNA ligase IIIα (LigIIIα) and other repair proteins to SSBs through an interaction between XRCC1, a scaffold protein and partner protein of nuclear LigIIIα, and PAR synthesized by PARP1 and to a lesser extent PARP2. Recently, these proteins have been implicated in a back-up pathway for joining Okazaki fragments that appears to have a critical function even in cells with no defect in the major LigI-dependent pathway. Finally, we discuss the effects of FDA-approved PARP1/2 inhibitors on DNA replication and repair in cancer and non-malignant cells and the potential utility of DNA ligase inhibitors as cancer therapeutics.

Keywords: DNA Repair inhibitors; DNA ligases; DNA repair; DNA replication; Poly (ADP-ribose) polymerases.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Alan E Tomkinson is an inventor on the US patent, US 9132,120 B1 “Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancer. The authors declare that they have no other competing interests.

Similar articles

References

    1. Cannan WJ, Pederson DS, Mechanisms and Consequences of Double-Strand DNA Break Formation in Chromatin, J Cell Physiol, 231 (2016) 3–14. - PMC - PubMed
    1. Li GM, Mechanisms and functions of DNA mismatch repair, Cell Res, 18 (2008) 85–98. - PubMed
    1. Spivak G, Nucleotide excision repair in humans, DNA Repair (Amst), 36 (2015) 13–18. - PMC - PubMed
    1. Gohil D, Sarker AH, Roy R, Base Excision Repair: Mechanisms and Impact in Biology, Disease, and Medicine, Int J Mol Sci, 24 (2023) 14186. - PMC - PubMed
    1. Tsao N, Ashour ME, Mosammaparast N, How RNA impacts DNA repair, DNA Repair (Amst), 131 (2023) 103564. - PMC - PubMed

LinkOut - more resources